logo

For the Inventor, By the Inventor

Tokyo, Japan

Kagari Fujita

This inventor holds 6 USPTO granted patents. Top assignee: Banyu Pharmaceutical Co. Ltd. Active years: 1992-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kagari Fujita. Retrieved from https://idiyas.com/inventor/kagari-fujita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 10.3

ph-index = 5

Forward Citations = 97(Granted Patents)


Location History:

  • Tsukuba, JP (1996)
  • Tokyo, JP (1992 - 1997)

Company Filing History:

goldMedal6 out of 237 
 
Banyu Pharmaceutical Co. Ltd
 patents

Years Active: 1992-1997

Loading Chart...
6 patents (USPTO):Explore Patents
1. 5691315 - Endothelin antagonistic peptide derivatives (1997-11-25),
2. 5614498 - Endothelin antagonistic substance (1997-03-25),
3. 5496928 - Endothelin antagonistic substance (1996-03-05),
4. 5470833 - Endothelin antagonistic peptide derivatives (1995-11-28),
5. 5444152 - Endothelin antagonistic peptide derivatives (1995-08-22),
6. 5114918 - Endothelin antagonistic cyclic pentapeptides (1992-05-19),

Title: Kagari Fujita: Innovator in Endothelin Antagonistic Peptides

Introduction

Kagari Fujita is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of endothelin antagonistic peptides. With a total of 6 patents to his name, Fujita's work has the potential to impact various medical conditions.

Latest Patents

Fujita's latest patents include innovative compounds that serve as antagonists of endothelin. One notable invention relates to endothelin antagonistic peptide derivatives, which are useful in treating conditions such as hypertension, pulmonary hypertension, and myocardial infarction. These compounds are designed to inhibit the binding of endothelin to its ETB receptor, providing therapeutic benefits for diseases associated with excess endothelin production.

Career Highlights

Fujita is currently associated with Banyu Pharmaceutical Co. Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential applications in treating serious health issues, including acute renal failure and asthma.

Collaborations

Fujita has collaborated with notable colleagues such as Kiyofumi Ishikawa and Takehiro Fukami. Their combined expertise has contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Kagari Fujita's contributions to the field of pharmaceuticals through his patents on endothelin antagonistic peptides highlight his role as a key innovator. His work not only showcases his dedication to medical advancements but also promises to improve the quality of life for many patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…